Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease Among Hospital Staff

References

• Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454–461. doi:10.1016/j.jhep.2021.05.003
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390. doi:10.1016/S2468-1253(22)00062-0
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–163. doi:10.3350/cmh.2021.0310
   PubMed Web of Science ®Google Scholar
• Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. doi:10.1007/s12072-020-10094-2
   PubMed Web of Science ®Google Scholar
• Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022;107(2):e745–e755. doi:10.1210/clinem/dgab644
   PubMed Web of Science ®Google Scholar
• Wang QX, Xue J, Shi MJ, et al. Association between metabolic dysfunction-associated fatty liver disease and the risk of cirrhosis in patients with chronic hepatitis B-A retrospective cohort study. Diabetes Metab Syndr Obes. 2022;15:2311–2322. doi:10.2147/DMSO.S369824
   PubMed Web of Science ®Google Scholar
• Lim GEH, Tang A, Ng CH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619–629.e7. doi:10.1016/j.cgh.2021.11.038
   PubMed Web of Science ®Google Scholar
• Ayada I, van Kleef LA, Alferink LJM, et al. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int. 2022;42(2):277–287. doi:10.1111/liv.15139
   PubMed Web of Science ®Google Scholar
• Chan KE, Koh TJL, Tang ASP, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10739607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700. doi:10.1210/clinem/dgac321
   PubMed Web of Science ®Google Scholar
• Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171.e5. doi:10.1016/j.cgh.2020.10.046
   PubMed Web of Science ®Google Scholar
• Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212. doi:10.1186/s12876-021-01782-w
   PubMed Web of Science ®Google Scholar
• Guan C, Fu S, Zhen D, et al. Metabolic (dysfunction)-associated fatty liver disease in Chinese patients with type 2 diabetes from a subcenter of the national metabolic management center. J Diabetes Res. 2022;2022:8429847. doi:10.1155/2022/8429847
   PubMed Web of Science ®Google Scholar
• Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651. doi:10.1038/s41575-022-00635-5
   PubMed Web of Science ®Google Scholar
• Fouad Y, Esmat G, Elwakil R, et al. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol. 2022;28(1):3–20. doi:10.4103/sjg.sjg_357_21
   PubMed Web of Science ®Google Scholar
• Shao CX, Ye J, Dong Z, et al. Steatosis grading consistency between controlled attenuation parameter and MRI-PDFF in monitoring metabolic associated fatty liver disease. Ther Adv Chronic Dis. 2021;12:20406223211033119. doi:10.1177/20406223211033119
   Web of Science ®Google Scholar
• Ye J, Zhuang X, Li X, et al. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation. Metabolism. 2022;136:155294. doi:10.1016/j.metabol.2022.155294
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–3351. doi:10.1210/jc.2010-0288
   PubMed Web of Science ®Google Scholar
• Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260. doi:10.1097/MOG.0000000000000823
   PubMed Web of Science ®Google Scholar
• Petta S, Eslam M, Valenti L, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: an age-dependent risk profiling study. Liver Int. 2017;37(9):1389–1396. doi:10.1111/liv.13397
   PubMed Web of Science ®Google Scholar
• Pennisi G, Enea M, Romero-Gomez M, et al. Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. Aliment Pharmacol Ther. 2022;55(5):604–615. doi:10.1111/apt.16763
   PubMed Web of Science ®Google Scholar
• Wang J, Su Z, Feng Y, Xi R, Liu J, Wang P. Comparison of several blood lipid-related indexes in the screening of non-alcoholic fatty liver disease in women: a cross-sectional study in the Pearl River Delta region of southern China. BMC Gastroenterol. 2021;21(1):482. doi:10.1186/s12876-021-02072-1
   PubMed Web of Science ®Google Scholar
• Sheng G, Lu S, Xie Q, Peng N, Kuang M, Zou Y. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. Lipids Health Dis. 2021;20(1):134. doi:10.1186/s12944-021-01561-2
   PubMed Web of Science ®Google Scholar
• Lee SB, Kim MK, Kang S, et al. Triglyceride glucose index is superior to the homeostasis model assessment of insulin resistance for predicting nonalcoholic fatty liver disease in Korean adults. Endocrinol Metab. 2019;34(2):179–186. doi:10.3803/EnM.2019.34.2.179
   Web of Science ®Google Scholar
• Campos-Murguía A, Román-Calleja BM, Toledo-Coronado IV, et al. Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19. Dig Liver Dis. 2021;53(5):525–533. doi:10.1016/j.dld.2021.01.019
   PubMedGoogle Scholar
• Wang J, Yan S, Cui Y, Chen F, Piao M, Cui W. The diagnostic and prognostic value of the triglyceride-glucose index in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): a systematic review and meta-analysis. Nutrients. 2022;14(23):4969. doi:10.3390/nu14234969
   PubMed Web of Science ®Google Scholar
• Crawford JH, Chacko BK, Kevil CG, Patel RP. The red blood cell and vascular function in health and disease. Antioxid Redox Signal. 2004;6(6):992–999. doi:10.1089/ars.2004.6.992
   PubMed Web of Science ®Google Scholar
• Wu S, Lin H, Zhang C, et al. Association between erythrocyte parameters and metabolic syndrome in urban Han Chinese: a longitudinal cohort study. BMC Public Health. 2013;13:989. doi:10.1186/1471-2458-13-989
   PubMed Web of Science ®Google Scholar
• Justo D, Marilus R, Mardi T, et al. The appearance of aggregated erythrocytes in the peripheral blood of individuals with insulin resistance. Diabetes Metab Res Rev. 2003;19(5):386–391. doi:10.1002/dmrr.391
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kubota N, Yamauchi T, et al. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. doi:10.3390/ijms22084156
   PubMed Web of Science ®Google Scholar
• Hong F, Guan L, Lin H, et al. Red blood cell count: an unrecognized risk factor for nonalcoholic fatty liver disease. Front Endocrinol. 2021;12:760981. doi:10.3389/fendo.2021.760981
   PubMed Web of Science ®Google Scholar
• Wang HL, Zhang H, Wu SL, et al. Red blood cell count has an independent contribution to the prediction of ultrasonography-diagnosed fatty liver disease. PLoS One. 2017;12(2):e0172027. doi:10.1371/journal.pone.0172027
   PubMed Web of Science ®Google Scholar
• Dai X, Zhou G, Xu L. Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease (MAFLD). PLoS One. 2022;17(12):e0279274. doi:10.1371/journal.pone.0279274
   PubMed Web of Science ®Google Scholar
• Ding SZ. Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer. World J Gastroenterol. 2020;26(10):995–1004. doi:10.3748/wjg.v26.i10.995
   PubMed Web of Science ®Google Scholar
• Mantovani A, Turino T, Altomari A, et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis. Metabolism. 2019;96:56–65. doi:10.1016/j.metabol.2019.04.012
   PubMed Web of Science ®Google Scholar
• Zhao XX, Wang RL, Liu MH, Huang XJ. Is the occurrence or reversal of nonalcoholic fatty liver disease associated with long-term helicobacter pylori infection among Chinese adults? A cohort study. Gastroenterol Res Pract. 2021;2021:6696473. doi:10.1155/2021/6696473
   PubMedGoogle Scholar
• Cheng KC, Lin YM, Liu CC, Wu KL, Lee KC. High red cell distribution width is associated with worse prognosis in early colorectal cancer after curative resection: a propensity-matched analysis. Cancers. 2022;14(4):945. doi:10.3390/cancers14040945
   PubMed Web of Science ®Google Scholar
• Xanthopoulos A, Tryposkiadis K, Dimos A, et al. Red blood cell distribution width in elderly hospitalized patients with cardiovascular disease. World J Cardiol. 2021;13(9):503–513. doi:10.4330/wjc.v13.i9.503
   PubMed Web of Science ®Google Scholar
• Chen M, Liao L, Yan J, Lin FQ. Predictive value of red blood cell distribution width for 1-year all-cause mortality in critically ill patients with acute myocardial infarction. Int J Gen Med. 2022;15:465–471. doi:10.2147/IJGM.S345109
   PubMed Web of Science ®Google Scholar
• Moreno C, Mueller S, Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70(2):273–283. doi:10.1016/j.jhep.2018.11.025
   PubMed Web of Science ®Google Scholar
• Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17(4):630–637.e8. doi:10.1016/j.cgh.2018.05.059
   PubMed Web of Science ®Google Scholar
• Michalak A, Guz M, Kozicka J, et al. Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease. World J Gastroenterol. 2022;28(38):5636–5647. doi:10.3748/wjg.v28.i38.5636
   PubMed Web of Science ®Google Scholar
• Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25(2):210–216. doi:10.1097/BOR.0b013e32835d951e
   PubMed Web of Science ®Google Scholar
• Lv Q, Xu D, Ma J, et al. Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation. Inflamm Res. 2021;70(1):127–137. doi:10.1007/s00011-020-01409-y
   PubMed Web of Science ®Google Scholar
• Hu X, Rong S, Wang Q, et al. Association between plasma uric acid and insulin resistance in type 2 diabetes: a Mendelian randomization analysis. Diabetes Res Clin Pract. 2021;171:108542. doi:10.1016/j.diabres.2020.108542
   PubMed Web of Science ®Google Scholar
• Han AL, Lee HK. Association of the metabolic dysfunction-associated fatty liver disease with serum uric acid-to-creatinine ratio. Metab Syndr Relat Disord. 2022;20(7):370–376. doi:10.1089/met.2022.0013
   PubMed Web of Science ®Google Scholar
• He J, Ye J, Sun Y, Feng S, Chen Y, Zhong B. The additive values of the classification of higher serum uric acid levels as a diagnostic criteria for metabolic-associated fatty liver disease. Nutrients. 2022;14(17):3587. doi:10.3390/nu14173587
   PubMed Web of Science ®Google Scholar
• Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal. 2005;7(7–8):1040–1052. doi:10.1089/ars.2005.7.1040
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293(2):C584–96. doi:10.1152/ajpcell.00600.2006
   PubMed Web of Science ®Google Scholar
• Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem. 2012;287(48):40732–40744. doi:10.1074/jbc.M112.399899
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237–241. doi:10.1038/nature04516
   PubMed Web of Science ®Google Scholar
• Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210–215. doi:10.1038/nri2725
   PubMed Web of Science ®Google Scholar
• Sun DQ, Jin Y, Wang TY, et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433. doi:10.1016/j.metabol.2020.154433
   PubMed Web of Science ®Google Scholar
• Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259–268. doi:10.1038/s41581-021-00519-y
   PubMed Web of Science ®Google Scholar
• Zhou XD, Cai J, Targher G, et al. CHESS-MAFLD consortium. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol. 2022;21(1):270. doi:10.1186/s12933-022-01697-0
   PubMed Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9
   PubMed Web of Science ®Google Scholar
• Eslam M, Ahmed A, Després JP, et al. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. Lancet Gastroenterol Hepatol. 2021;6(9):743–753. doi:10.1016/S2468-1253(21)00132-1
   PubMed Web of Science ®Google Scholar
• Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol. 2021;6(7):578–588. doi:10.1016/S2468-1253(21)00020-0
   PubMed Web of Science ®Google Scholar